



CN012-0020 Study patient flyer



What is the purpose of the CN012-0020 Study?

The CN012-0020 Study is researching a study drug called KarXT. The goal of this study is to find out how safe KarXT is and how well it may work to help teenagers who have schizophrenia.



What study drug is being researched?

KarXT (xanomeline-trospium chloride) is the study drug being researched in the CN012-0020 Study. It is a pill that is taken by mouth two times a day. Researchers hope to find out how safe KarXT is and how well it may work to help teenagers who have schizophrenia.



What should participants expect?

Participation will last about 11 weeks and consist of the following periods.



Study period details

- **Screening period (up to 4 weeks):** Includes at least one visit. During this period, you or your loved one will have health tests and assessments so the study doctor can determine if the study is a good match.
- **Double-blind treatment period (5 weeks):** Includes six visits and one phone call. You or your loved one will be randomly assigned to receive either KarXT or a placebo. They will take one pill twice daily.
 - The placebo is a pill that looks just like KarXT but doesn't have any active investigational medicine in it. Using a placebo in a study helps researchers find the most accurate results by giving them something to compare the study medicine to.
- **Optional open-label extension study (1 year):** Includes up to 15 visits and four phone calls. If you or your loved one completes the five-week double-blind treatment period, they may have the option to join this longer open-label study. During this time, they will take KarXT every day and go to regular study visits.
 - There is no placebo in the extension study, so if you or your loved one received the placebo before, they would switch to KarXT.
- **Follow-up period (2 weeks):** Includes at least one visit. You or your loved one will stop taking the study pill and attend a visit so that the study team can check on their health.



Who qualifies for the CN012-0020 Study?

Eligible participants must:

- Be 13–17 years of age
- Be diagnosed with schizophrenia
- Be willing to stop taking your current schizophrenia medication(s) during the study
- Have a parent or guardian who can help with study requirements (things like driving to visits and remembering to take the study pills)

There are more rules for who can join. The study doctor can explain those to you.



Where can I learn more about the CN012-0020 Study?

For more information about this clinical research study, please visit [BMSClinicalTrials.com/us/en/clinical-trials/NCT07288567](https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT07288567) or contact the study coordinator listed here.

Study doctor: _____

Phone number: _____

Study coordinator: _____

Phone number: _____

Study site address: _____

You or your loved one will receive the study pill, study-related medical exams, and study-related laboratory tests at no cost. Support for study-related travel costs for you and your loved one may be available.



Study timeline

Screening period
Up to 4 weeks, 1 visit

Double-blind treatment period
5 weeks, 6 visits, and 1 phone call

Optional open-label extension study
About 1 year, up to 15 visits,
and 4 phone calls

Follow-up period
2 weeks, 1 visit